STING1 and neoplasm: Encouraged by our recent efforts in the development of tumor-targeted, triple-action platinum(iv) prodrugs bearing immunomodulators, such as the indoleamine 2,3-dioxygenase inhibitor 1-methyl-d-tryptophan,12 and envisioned by combining STING agonists and platinum(iv)-based chemotherapy for achievement of a synergistic antitumor effect, we investigated the potential of oxaliplatin(iv) prodrugs bearing the STING agonists SR-717 and MSA-2.